Previous close | 30.10 |
Open | 29.30 |
Bid | 30.80 |
Ask | 33.50 |
Strike | 220.00 |
Expiry date | 2025-01-17 |
Day's range | 29.30 - 30.10 |
Contract range | N/A |
Volume | |
Open interest | 91 |
Key Insights Insulet's estimated fair value is US$206 based on 2 Stage Free Cash Flow to Equity Insulet's US$230 share...
Insulet Corp, headquartered in Acton, Massachusetts, is a medical device company primarily engaged in the development, manufacture, and sale of insulin infusion systems for people with insulin-dependent diabetes. Over the past year, Timothy Scannell has sold a total of 15,300 shares of Insulet Corp and has not made any purchases of the stock. Shares of Insulet Corp were trading at $225.84 on the day of the sale.
Brown Capital Management, an investment management company, released its “The Brown Capital Management Mid Company Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. The Mid Company Fund (Institutional shares) returned -7.85 % in the quarter significantly underperforming -3.21% return for the Russell Midcap Growth Index. The strategy focuses […]